Gliclazide: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
No edit summary
 
Line 1: Line 1:
{{DrugProjectFormSinglePage
{{drugbox
|genericName=Gliclazide
| IUPAC_name = 3-(7-azabicyclo[3.3.0]oct-7-yl)-<br />1-(4-methylphenyl)sulfonyl-urea
|aOrAn=a
| image =
|drugClass=hypoglycemic agent
| CAS_number = 21187-98-4
|hasBlackBoxWarning=Yes
| ATC_prefix = A10
|adverseReactions=<!--Black Box Warning-->
| ATC_suffix = BB09
|blackBoxWarningTitle=<span style="color:#FF0000;">ConditionName: </span>
| PubChem = 3475
|blackBoxWarningBody=<i><span style="color:#FF0000;">ConditionName: </span></i>
| DrugBank = APRD00460
 
| C = 15 |H = 21 |N = 3 |O = 3 |S = 1
* Content
| molecular_weight = 323.412 [[Gram|g]]/[[Mole (unit)|mol]]
 
| bioavailability =  
<!--Adult Indications and Dosage-->
| protein_bound =  
 
| metabolism =  
<!--FDA-Labeled Indications and Dosage (Adult)-->
| elimination_half-life =  
|fdaLIADAdult======Condition1=====
| pregnancy_category =  
 
| legal_status =  
* Dosing Information
| routes_of_administration =  
 
}}
:* Dosage
 
=====Condition2=====
 
* Dosing Information
 
:* Dosage
 
=====Condition3=====
 
* Dosing Information
 
:* Dosage
 
=====Condition4=====
 
* Dosing Information
 
:* Dosage
 
<!--Off-Label Use and Dosage (Adult)-->
 
<!--Guideline-Supported Use (Adult)-->
|offLabelAdultGuideSupport======Condition1=====
 
* Developed by:
 
* Class of Recommendation:
 
* Strength of Evidence:
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
 
<!--Non–Guideline-Supported Use (Adult)-->
|offLabelAdultNoGuideSupport======Condition1=====
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
 
<!--Pediatric Indications and Dosage-->
 
<!--FDA-Labeled Indications and Dosage (Pediatric)-->
|fdaLIADPed======Condition1=====
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>FDA-Labeled Use</i> of {{PAGENAME}} in pediatric patients.
 
<!--Off-Label Use and Dosage (Pediatric)-->
 
<!--Guideline-Supported Use (Pediatric)-->
|offLabelPedGuideSupport======Condition1=====
 
* Developed by:
 
* Class of Recommendation:
 
* Strength of Evidence:
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
 
<!--Non–Guideline-Supported Use (Pediatric)-->
|offLabelPedNoGuideSupport======Condition1=====
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
 
<!--Contraindications-->
|contraindications=* Condition1
 
<!--Warnings-->
|warnings=* Description
 
====Precautions====
 
* Description
 
<!--Adverse Reactions-->
 
<!--Clinical Trials Experience-->
|clinicalTrials=There is limited information regarding <i>Clinical Trial Experience</i> of {{PAGENAME}} in the drug label.
 
=====Body as a Whole=====
 
 
 
 
=====Cardiovascular=====
 
 
 
 
=====Digestive=====
 
 
 
 
=====Endocrine=====
 
 
 
 
=====Hematologic and Lymphatic=====
 
 
 
 
=====Metabolic and Nutritional=====
 
 
 
 
=====Musculoskeletal=====
 
 
 
 
=====Neurologic=====
 
 
 
 
=====Respiratory=====
 
 
 
 
=====Skin and Hypersensitivy Reactions=====
 
 
 
 
=====Special Senses=====
 
 
 
 
=====Urogenital=====
 
 
 
 
=====Miscellaneous=====
 
 
 
<!--Postmarketing Experience-->
|postmarketing=There is limited information regarding <i>Postmarketing Experience</i> of {{PAGENAME}} in the drug label.
 
=====Body as a Whole=====
 
 
 
=====Cardiovascular=====
 
 
 
=====Digestive=====
 
 
 
=====Endocrine=====
 
 
 
=====Hematologic and Lymphatic=====
 
 
 
=====Metabolic and Nutritional=====
 
 
 
=====Musculoskeletal=====
 
 
 
=====Neurologic=====
 
 
 
=====Respiratory=====
 
 
 
=====Skin and Hypersensitivy Reactions=====
 
 
 
=====Special Senses=====
 
 
 
=====Urogenital=====
 
 
 
=====Miscellaneous=====
 
 
 
<!--Drug Interactions-->
|drugInteractions=* Drug
:* Description
 
<!--Use in Specific Populations-->
|useInPregnancyFDA=* '''Pregnancy Category'''
|useInPregnancyAUS=* '''Australian Drug Evaluation Committee (ADEC) Pregnancy Category'''
 
There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of {{PAGENAME}} in women who are pregnant.
|useInLaborDelivery=There is no FDA guidance on use of {{PAGENAME}} during labor and delivery.
|useInNursing=There is no FDA guidance on the use of {{PAGENAME}} with respect to nursing mothers.
|useInPed=There is no FDA guidance on the use of {{PAGENAME}} with respect to pediatric patients.
|useInGeri=There is no FDA guidance on the use of {{PAGENAME}} with respect to geriatric patients.
|useInGender=There is no FDA guidance on the use of {{PAGENAME}} with respect to specific gender populations.
|useInRace=There is no FDA guidance on the use of {{PAGENAME}} with respect to specific racial populations.
|useInRenalImpair=There is no FDA guidance on the use of {{PAGENAME}} in patients with renal impairment.
|useInHepaticImpair=There is no FDA guidance on the use of {{PAGENAME}} in patients with hepatic impairment.
|useInReproPotential=There is no FDA guidance on the use of {{PAGENAME}} in women of reproductive potentials and males.
|useInImmunocomp=There is no FDA guidance one the use of {{PAGENAME}} in patients who are immunocompromised.
 
<!--Administration and Monitoring-->
|administration=* Oral
 
* Intravenous
|monitoring=There is limited information regarding <i>Monitoring</i> of {{PAGENAME}} in the drug label.


* Description
{{SI}}


<!--IV Compatibility-->
|IVCompat=There is limited information regarding <i>IV Compatibility</i> of {{PAGENAME}} in the drug label.


<!--Overdosage-->
==Overview==
|overdose====Acute Overdose===
'''Gliclazide''' is an oral hypoglycemic ([[anti-diabetic drug]]) and is classified as a [[sulfonylurea]]. It is marketed as '''Diamicron MR®'''.
'''DIAMICRON MR''' is also distributed as:
Diabeton MR, Diamicron 30mg, Diamicron LM 30mg, Diamicron MR 30 mg, Diamicron Uno 30mg, Dianormax MR, Diaprel MR and Uni Diamicron.


====Signs and Symptoms====
== Form and Composition: ==
Each tablet contains 80 mg of gliclazide.


* Description
Not marketed in the United States.


====Management====
== Indication: ==
Control of [[hyperglycemia]] in gliclazide responsive [[diabetes mellitus]] of stable, mild, non-[[ketosis]] prone, maturity onset or adult type which cannot be controlled by proper dietary management and exercise, or when [[insulin]] therapy is not appropriate.


* Description
== Dosage: ==
40 to 240 mg depending on response, once or twice daily before food, no more that 160 mg at a time.


===Chronic Overdose===
== Properties: ==
 
There is limited information regarding <i>Chronic Overdose</i> of {{PAGENAME}} in the drug label.
[[Hypoglycemic]] [[sulfonylurea]], restoring first peak of [[insulin]] secretion, increasing [[insulin sensitivity]].
 
[[Glycemia]]-independent hemovascular effects, [[antioxidant]] effect.  
<!--Pharmacology-->
No active circulating [[metabolite]]s.  
 
<!--Drug box 2-->
|drugBox=<!--Mechanism of Action-->
|mechAction=*
 
<!--Structure-->
|structure=*
 
: [[File:{{PAGENAME}}01.png|thumb|none|600px|This image is provided by the National Library of Medicine.]]
 
<!--Pharmacodynamics-->
|PD=There is limited information regarding <i>Pharmacodynamics</i> of {{PAGENAME}} in the drug label.
 
<!--Pharmacokinetics-->
|PK=There is limited information regarding <i>Pharmacokinetics</i> of {{PAGENAME}} in the drug label.
 
<!--Nonclinical Toxicology-->
|nonClinToxic=There is limited information regarding <i>Nonclinical Toxicology</i> of {{PAGENAME}} in the drug label.
 
<!--Clinical Studies-->
|clinicalStudies=There is limited information regarding <i>Clinical Studies</i> of {{PAGENAME}} in the drug label.
 
<!--How Supplied-->
|howSupplied=*
|packLabel=<!--Patient Counseling Information-->
|fdaPatientInfo=There is limited information regarding <i>Patient Counseling Information</i> of {{PAGENAME}} in the drug label.
 
<!--Precautions with Alcohol-->
|alcohol=* Alcohol-{{PAGENAME}} interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
 
<!--Brand Names-->
|lookAlike=* A® — B®<ref name="www.ismp.org">{{Cite web  | last =  | first =  | title = http://www.ismp.org | url = http://www.ismp.org | publisher =  | date =  }}</ref>
 
<!--Drug Shortage Status-->
|drugShortage=
}}
{{PillImage
|fileName=No image.jpg
}}
{{LabelImage
|fileName={{PAGENAME}}11.png
}}
{{LabelImage
|fileName={{PAGENAME}}11.png
}}
<!--Pill Image-->


== Contraindications: ==
[[type 1 diabetes]],
hypersensitivity to [[sulfonylureas]],
severe [[renal failure|renal]] or [[hepatic failure]],
[[pregnancy]] and [[lactation]],
[[miconazole]] coprescription.


== Interactions: ==
[[Hyperglycemic]] action may be caused by [[danazol]], [[chlorpromazine]], [[glucocorticoids]], [[progestogens]], β-2 agonists.
Its [[hypoglycemic]] action may be potentiated by [[phenylbutazone]], [[alcohol]], [[fluconazole]], [[β-blockers]], possibly [[ACE inhibitors]].


<!--Label Display Image-->
== Adverse effects: ==
[[Hypoglycemia]], [[gastrointestinal]] disturbance (reported), [[skin]] reactions (rare), [[hematological]] disorders (rare), [[hepatic]] [[enzyme]] rises (exceptional).


== Overdosage: ==
Possible severe [[hypoglycemia]] requiring urgent [[IV]] [[glucose]] and monitoring.


==External links==
*[http://www.diamicronmr.com Official site for Diamicron MR]


{{Oral_hypoglycemics}}


[[Category:Sulfonylureas]]
[[Category:Endocrinology]]


<!--Category-->
[[fr:Gliclazide]]


[[Category:Drug]]
{{WikiDoc Help Menu}}
{{WikiDoc Sources}}

Latest revision as of 17:55, 24 December 2014

Gliclazide
Clinical data
ATC code
Identifiers
CAS Number
PubChem CID
DrugBank
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC15H21N3O3S
Molar mass323.412 g/mol

WikiDoc Resources for Gliclazide

Articles

Most recent articles on Gliclazide

Most cited articles on Gliclazide

Review articles on Gliclazide

Articles on Gliclazide in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Gliclazide

Images of Gliclazide

Photos of Gliclazide

Podcasts & MP3s on Gliclazide

Videos on Gliclazide

Evidence Based Medicine

Cochrane Collaboration on Gliclazide

Bandolier on Gliclazide

TRIP on Gliclazide

Clinical Trials

Ongoing Trials on Gliclazide at Clinical Trials.gov

Trial results on Gliclazide

Clinical Trials on Gliclazide at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Gliclazide

NICE Guidance on Gliclazide

NHS PRODIGY Guidance

FDA on Gliclazide

CDC on Gliclazide

Books

Books on Gliclazide

News

Gliclazide in the news

Be alerted to news on Gliclazide

News trends on Gliclazide

Commentary

Blogs on Gliclazide

Definitions

Definitions of Gliclazide

Patient Resources / Community

Patient resources on Gliclazide

Discussion groups on Gliclazide

Patient Handouts on Gliclazide

Directions to Hospitals Treating Gliclazide

Risk calculators and risk factors for Gliclazide

Healthcare Provider Resources

Symptoms of Gliclazide

Causes & Risk Factors for Gliclazide

Diagnostic studies for Gliclazide

Treatment of Gliclazide

Continuing Medical Education (CME)

CME Programs on Gliclazide

International

Gliclazide en Espanol

Gliclazide en Francais

Business

Gliclazide in the Marketplace

Patents on Gliclazide

Experimental / Informatics

List of terms related to Gliclazide


Overview

Gliclazide is an oral hypoglycemic (anti-diabetic drug) and is classified as a sulfonylurea. It is marketed as Diamicron MR®. DIAMICRON MR is also distributed as: Diabeton MR, Diamicron 30mg, Diamicron LM 30mg, Diamicron MR 30 mg, Diamicron Uno 30mg, Dianormax MR, Diaprel MR and Uni Diamicron.

Form and Composition:

Each tablet contains 80 mg of gliclazide.

Not marketed in the United States.

Indication:

Control of hyperglycemia in gliclazide responsive diabetes mellitus of stable, mild, non-ketosis prone, maturity onset or adult type which cannot be controlled by proper dietary management and exercise, or when insulin therapy is not appropriate.

Dosage:

40 to 240 mg depending on response, once or twice daily before food, no more that 160 mg at a time.

Properties:

Hypoglycemic sulfonylurea, restoring first peak of insulin secretion, increasing insulin sensitivity. Glycemia-independent hemovascular effects, antioxidant effect. No active circulating metabolites.

Contraindications:

type 1 diabetes, hypersensitivity to sulfonylureas, severe renal or hepatic failure, pregnancy and lactation, miconazole coprescription.

Interactions:

Hyperglycemic action may be caused by danazol, chlorpromazine, glucocorticoids, progestogens, β-2 agonists. Its hypoglycemic action may be potentiated by phenylbutazone, alcohol, fluconazole, β-blockers, possibly ACE inhibitors.

Adverse effects:

Hypoglycemia, gastrointestinal disturbance (reported), skin reactions (rare), hematological disorders (rare), hepatic enzyme rises (exceptional).

Overdosage:

Possible severe hypoglycemia requiring urgent IV glucose and monitoring.

External links

Template:Oral hypoglycemics


Template:WikiDoc Sources

Retrieved from "https://www.wikidoc.org/index.php?title=Gliclazide&oldid=1050655"